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Pharmaceutical benefits scheme cost recovery 
Abstract 
Since the beginning of 2010 the Australian Government has applied cost recovery to the listing process of 
the Pharmaceutical Benefits Scheme (PBS). Drug companies seeking to list their drugs on the PBS or 
vaccines on the National Immunisation Program pay a fee at two key points - upon lodgement of the 
application and at the pricing stage. The lodgement fee relates to the evaluation work of the 
Pharmaceutical Benefits Advisory Committee (PBAC) and all of its supporting administrative functions. 
The pricing fee relates to the pricing work of the Pharmaceutical Benefits Pricing Authority and its 
supporting functions. Companies that want an independent review of a PBAC recommendation to not list 
a drug on the PBS will also pay. The fees are not trivial - $119 500 for a major PBAC evaluation, $25 000 
for a complex 'pricing' and $119 500 for an independent review. Hardly spare change, even for a 
pharmaceutical company. So what is the purpose of the cost recovery scheme and what are the likely 
consequences? 
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editorial
In this issue…
The cost of the Pharmaceutical Benefits Scheme will always 
be a topic for debate, but it is important to know that 
the evaluations of cost-effectiveness are assessed by the 
independent Pharmaceutical Benefits Advisory Committee. 
Glenn Salkeld reassures us that the introduction of 
evaluation fees will not compromise this independence.
Independence is also important when assessing 
information about medicines. Rosalind Tindale tells us 
where to find independent sources of drug information.
Genetic information has changed the way haemochromatosis 
is investigated. Andrew St John, Katherine Stuart and 
Darrell Crawford review how to make the diagnosis.
The prognosis for patients with HIV has improved, but 
regular monitoring and adherence to treatment are 
essential. Tom Turnbull provides advice on how general 
practitioners can assist in management.
The management of sleep apnoea may also involve a range 
of health professionals. Stuart MacKay outlines some of the 
treatment options.
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Since the beginning of 2010 the Australian Government has 
applied cost recovery to the listing process of the Pharmaceutical 
Benefits Scheme (PBS). Drug companies seeking to list their 
drugs on the PBS or vaccines on the National Immunisation 
Program pay a fee at two key points – upon lodgement of the 
application and at the pricing stage.1 The lodgement fee relates 
to the evaluation work of the Pharmaceutical Benefits Advisory 
Committee (PBAC) and all of its supporting administrative 
functions. The pricing fee relates to the pricing work of the 
Pharmaceutical Benefits Pricing Authority and its supporting 
functions. Companies that want an independent review of 
a PBAC recommendation to not list a drug on the PBS will 
also pay. The fees are not trivial – $119 500 for a major PBAC 
evaluation, $25 000 for a complex 'pricing' and $119 500 for 
an independent review.2 Hardly spare change, even for a 
pharmaceutical company. So what is the purpose of the cost 
recovery scheme and what are the likely consequences? 
The stated purpose is to recover the cost of the services 
provided (evaluation and pricing) and to promote efficient 
allocation of resources.1 Depending on your point of view it 
is either an attempt to gouge the pockets of industry or a 'fair 
cop guv'. After all, the pharmaceutical industry does very nicely 
from PBS price subsidies, and so does the Australian public. 
All parties benefit from the PBS – the key question is whether 
cost recovery threatens the very process that has delivered safe, 
timely and affordable access to prescribed medicines for all 
Australians. 
Some of the early response to the cost recovery proposal 
has been reminiscent of the reaction when the PBAC started 
to assess the cost-effectiveness of drugs (National Health 
Amendment Bill 1987). It was feared that the extra cost of 
preparing submissions would result in Australia missing out 
on new drugs. However, the PBAC cost-effectiveness process 
is designed to reward sponsors with higher prices for drugs 
that provide greater clinical benefit than the drugs which 
are currently available. It does not reward those drugs that 
do not confer additional clinical benefit. Without the cost-
effectiveness requirement the PBS would probably have sunk 
under the weight of its own success. It may still do so unless 
pharmaceutical expenditure is kept under tight control. There 
are, however, legitimate concerns about cost recovery.
The first concern is that PBS cost recovery may be the straw 
that will break the camel's back. The pharmaceutical industry 
is already carrying the load of lower profits, fewer blockbuster 
drugs in the pipeline and the high cost of getting a drug to 
market. Critics of cost recovery argue that some new drugs 
may never enter the Australian market due to higher costs 
of registration and PBS listing (or face lengthy delays in 
reaching our shores). Those that do will be more expensive (as 
companies will pass on the extra cost of PBS listing) and smaller 
companies may be driven out of the market. Furthermore, cost 
recovery may discourage development of drugs aimed at a 
lower volume market. 
Let us get some perspective here. In 2008–09, the Australian 
Government spent more than $7.679 billion on pharmaceutical 
benefits.3 That is taxpayer dollars that not only provide health 
benefits to millions of Australians but also contribute directly to 
bottom line industry profits. At face value industry can afford 
the extra impost of cost recovery. It is unlikely that new drugs 
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will be prevented or delayed in reaching the Australian market. 
The Australian pharmaceutical market is a competitive one 
and 'if a company decides not to launch a particular product 
in Australia, then competitors' products come in'.4 If there is 
no competitor then it is possible that a sole manufacturer may 
decide not to introduce a new product to the Australian market. 
It is a commercial decision. If cost recovery fees alone swing the 
manufacturer's net present value calculation of a new drug from 
a decision to submit (to the Therapeutic Goods Administration 
(TGA) and subsequently to PBAC) to 'not submit', then the case 
for registration and PBS listing is likely to have been marginal in 
the first place. 
Another concern is that cost recovery may compromise the 
independence of the PBAC, because it will be paid by the drug 
companies. This fear appears to be unfounded because the 
PBAC has no direct pecuniary interest in the process. All the 
income from cost recovery fees goes into consolidated revenue 
rather than to the PBAC itself. Neither the Department of Health 
and Ageing nor the PBAC would actually see any of the 'cost 
recovery' funds. Historically the PBAC has shown itself to be 
strongly independent. Since 1998–99 the TGA has operated on 
a full cost recovery basis. I have not seen evidence to suggest 
that the TGA has been compromised by the introduction of cost 
recovery. 
It is fair to say that a lot of effort has gone into making the PBAC 
process more transparent and responsive to the needs of drug 
companies and this preceded the introduction of cost recovery. 
The industry's expectations of the process may increase as a 
result of the new fees, with an understandable desire for quicker 
turnaround of PBAC submissions. Time will tell how the PBAC 
responds to the concurrent demands of meeting their legislative 
requirements and managing what is the inherently adversarial 
nature of negotiating drug prices. 
of course there are instances when the imposition of the cost 
recovery fee is not in the public interest. Under the National 
Health (Pharmaceuticals and Vaccines – Cost Recovery) 
Regulations 20092 an exemption may be granted in respect 
of orphan drugs, the temporary supply of drugs or changes 
to an existing PBS listing. A fee waiver may be granted if 'the 
application involves the public interest and payment of the 
fee would make the application financially unviable'. This may 
apply when the patient population is not large enough to make 
the application financially viable, the product is to be used for 
palliative care or as a paediatric medicine, or for treatment of 
Aboriginal or Torres Strait Islander people.
For any change in policy it pays to be vigilant and monitor 
any unintended consequences. If experience is anything to 
go by, the PBAC process will survive. Numerous reviews and 
a few detractors have not weakened the inherent strength of 
a legislated process that supports evidence-based decision 
making.  
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Professor Salkeld has received an honorarium from 
Pfizer for teaching a short course on 'cost-effectiveness of 
pharmaceuticals'.
Denosumab
editor, – We welcome being recognised for transparency 
in supplying Therapeutic Goods Administration (TGA) 
evaluation data to Australian Prescriber to assist in the 
preparation of the new drug comment about denosumab 
(Prolia) (Aust Prescr 2010;33:194).
We were, however, surprised to read a statement, based on 
a meta-analysis1 that 'denosumab was not associated with 
a significant reduction in fracture risk in postmenopausal 
women', despite your review having previously described a 
clinical trial which showed statistically significant reductions 
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